Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StromaForte in Musculoskeletal Injuries and Degeneration
NCT06074783Phase 2Recruiting
- Sponsor
- Cellcolabs
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of StromaForte in Musculoskeletal injury, musculoskeletal degeneration, sponsored by Cellcolabs. Started Oct 2023; status: recruiting.
02
Drugs
StromaForte
03
Conditions
Musculoskeletal injurymusculoskeletal degeneration
Beyond the preview
Go deeper on NCT06074783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06074783.